These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 15718695)

  • 21. INFOTECHpharma '99--the information revolution in the pharmaceutical industry. 28-29 January 1999, London, UK.
    Kibble A; Ekuban L; Muhsin M
    IDrugs; 1999 Apr; 2(4):300-3. PubMed ID: 16158348
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Using RNAi in the clinic.
    Dev KK
    IDrugs; 2006 Apr; 9(4):279-82. PubMed ID: 16596482
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nontraditional approaches to first-in-human studies to increase efficiency of drug development: will microdose studies make a significant impact?
    Boyd RA; Lalonde RL
    Clin Pharmacol Ther; 2007 Jan; 81(1):24-6. PubMed ID: 17185993
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of systems biology and biosimulation on drug discovery and development.
    Michelson S
    Mol Biosyst; 2006 Jun; 2(6-7):288-91. PubMed ID: 16880946
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemical process research and development in the 21st century: challenges, strategies, and solutions from a pharmaceutical industry perspective.
    Federsel HJ
    Acc Chem Res; 2009 May; 42(5):671-80. PubMed ID: 19338294
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The use of high-fidelity human patient simulation as an evaluative tool in the development of clinical research protocols and procedures.
    Wright MC; Taekman JM; Barber L; Hobbs G; Newman MF; Stafford-Smith M
    Contemp Clin Trials; 2005 Dec; 26(6):646-59. PubMed ID: 16226924
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of pharmacophore modeling in drug design.
    Guner OF
    IDrugs; 2005 Jul; 8(7):567-72. PubMed ID: 15973565
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Application of predictive biosimulation within pharmaceutical clinical development: examples of significance for translational medicine and clinical trial design.
    Kansal AR; Trimmer J
    Syst Biol (Stevenage); 2005 Dec; 152(4):214-20. PubMed ID: 16986263
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fostering culture and optimizing organizational structure for implementing model-based drug development.
    Zhang L; Allerheiligen SR; Lalonde RL; Stanski DR; Pfister M
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):146S-150S. PubMed ID: 20881228
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of genomics in clinical trial design.
    Simon R
    Clin Cancer Res; 2008 Oct; 14(19):5984-93. PubMed ID: 18829477
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Can open-source R&D reinvigorate drug research?
    Munos B
    Nat Rev Drug Discov; 2006 Sep; 5(9):723-9. PubMed ID: 16915233
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, development, and evaluation of an online virtual emergency department for training trauma teams.
    Youngblood P; Harter PM; Srivastava S; Moffett S; Heinrichs WL; Dev P
    Simul Healthc; 2008; 3(3):146-53. PubMed ID: 19088658
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The promise of a virtual lab in drug discovery.
    Rauwerda H; Roos M; Hertzberger BO; Breit TM
    Drug Discov Today; 2006 Mar; 11(5-6):228-36. PubMed ID: 16580600
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Erosion of the principal investigator role in a climate of industry dominance.
    Rowinsky EK
    Eur J Cancer; 2005 Oct; 41(15):2206-9. PubMed ID: 16162405
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modelling iterative compound optimisation using a self-avoiding walk.
    Delaney J
    Drug Discov Today; 2009 Feb; 14(3-4):198-207. PubMed ID: 19027874
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Integrating research and development: the emergence of rational drug design in the pharmaceutical industry.
    Adam M
    Stud Hist Philos Biol Biomed Sci; 2005 Sep; 36(3):513-37. PubMed ID: 16137601
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The economics of drug discovery and the ultimate valuation of pharmacotherapies in the marketplace.
    Sollano JA; Kirsch JM; Bala MV; Chambers MG; Harpole LH
    Clin Pharmacol Ther; 2008 Aug; 84(2):263-6. PubMed ID: 18547999
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Strategic applications of toxicogenomics in early drug discovery.
    Ryan TP; Stevens JL; Thomas CE
    Curr Opin Pharmacol; 2008 Oct; 8(5):654-60. PubMed ID: 18760379
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Driving earlier clinical attrition: if you want to find the needle, burn down the haystack. Considerations for biomarker development.
    Peck RW
    Drug Discov Today; 2007 Apr; 12(7-8):289-94. PubMed ID: 17395088
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.